FRANKFURT, Oct 25 (Reuters) - Sanofi's finance chief on Friday said the company won't be affected by Novo Nordisk's controlling shareholder's decision to acquire contract drug manufacturer Catalent , adding the deal made sense for its rival.
"They desperately need capacity so it makes sense for them," Sanofi CFO Francois-Xavier Roger said in a media call after the release of third-quarter results.
He added Novo paid a "very heavy price to get access to the capacity", given very strong demand for weight-loss drugs.
Swiss drugmaker Roche on Wednesday joined peer Eli Lilly in voicing concern over the planned Catalent takeover, saying it could hit competition in the booming weight-loss drug industry.
(Reporting by Ludwig Burger)
((ludwig.burger@thomsonreuters.com; +49 30 220133634;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。